Company intelligence / Profile preview

Kenjockety Biotechnology, Inc.

Los Altos, California, United Stateskenjocketybio.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

The company is developing bispecific antibodies targeting efflux pumps and tumor-associated antigens to address drug resistance in cancer. They have generated in vivo proof of concept data in multiple tumor models showing potential for both combination and single agent approaches.

Therapeutic areas: Oncology
Modalities: Bispecific antibodies (BsAbs)
Industry: Biotech

Drug pipeline

8 assets

B1-1420

Preclinical

7 more assets in the full pipeline.

Request access →

Partnerships

Seeking industry partners for research collaborations

Beyond the preview

Go deeper on Kenjockety Biotechnology, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kenjockety Biotechnology, Inc..

Explore the full profile